Citadel Advisors
SPRO icon

Citadel Advisors’s Spero Therapeutics SPRO Stock Holding History

Citadel Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.5K Buy
+26,700
New +$63.4K ﹤0.01% 12307
2025
Q2 		– Sell
-9,300
Closed -$6.7K – 14931
2025
Q1 		$6.7K Buy
9,300
+9,100
+4,550% +$7.68K ﹤0.01% 13735
2024
Q4 		$206 Hold
200
– – ﹤0.01% 14366
2024
Q3 		$268 Sell
200
-300
-60% -$402 ﹤0.01% 14062
2024
Q2 		$650 Buy
+500
New +$754 ﹤0.01% 13942
2023
Q3 		– Sell
-100
Closed -$145 – 15062
2023
Q2 		$145 Buy
+100
New +$171 ﹤0.01% 14205
2022
Q3 		– Sell
-40,800
Closed -$30K – 13552
2022
Q2 		$30K Buy
40,800
+24,000
+143% +$69.8K ﹤0.01% 12228
2022
Q1 		$146K Buy
16,800
+1,200
+8% +$12.3K ﹤0.01% 11879
2021
Q4 		$250K Sell
15,600
-17,800
-53% -$283K ﹤0.01% 11355
2021
Q3 		$615K Sell
33,400
-4,900
-13% -$78.6K ﹤0.01% 9375
2021
Q2 		$535K Buy
38,300
+7,300
+24% +$102K ﹤0.01% 9918
2021
Q1 		$456K Sell
31,000
-300
-1% -$5.28K ﹤0.01% 9870
2020
Q4 		$607K Buy
31,300
+15,300
+96% +$239K ﹤0.01% 7791
2020
Q3 		$179K Buy
+16,000
New +$189K ﹤0.01% 8896

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's SPRO Position: Q1 2026 in Review

Citadel Advisors reduced its Spero Therapeutics (SPRO) stake by 5.4% in Q1 2026, selling an estimated $50.8K and leaving 376,458 shares worth $881K. The position accounts for ﹤0.01% of the portfolio, ranked #7955.

Citadel Advisors first reported a position in SPRO in Q3 2020 and has held it in 15 quarters since. The position peaked at $927K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Citadel Advisors held 376,458 shares of Spero Therapeutics worth $881K as of Q1 2026.
  • Citadel Advisors sold 21,406 Spero Therapeutics shares in Q1 2026, an estimated $50.8K.
  • Spero Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7955 holding.
  • Citadel Advisors first reported a position in Spero Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Citadel Advisors's Spero Therapeutics position peaked at $927K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.